FDA 510(k) clearance expands da Vinci 5 indications to include certain cardiac proceduresSUNNYVALE, Calif., Jan. 26, 2026 (GLOBE NEWSWIRE) -- Intuitive (NASDAQ: ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, today announced that the U.S. Food and Drug Administration (FDA) has cleared the da Vinci 5 system for certain cardiac procedures, including mitral valve repair and IMA (internal mammary artery) mobilization for cardiac revascularization. Cardi ...

Core Viewpoint - A class action lawsuit has been filed against Integer Holdings Corporation for allegedly misleading investors regarding its business performance and sales guidance [1][3]. Group 1: Lawsuit Details - The lawsuit is on behalf of investors who acquired Integer securities between July 25, 2024, and October 22, 2025 [1][2]. - Investors have until February 9, 2026, to seek appointment as lead plaintiff representatives [2]. Group 2: Allegations Against Integer - The company is accused of overstating its competitive position and failing to disclose declining sales of electrophysiology devices [3]. - Integer mischaracterized its growth drivers, leading to misleading representations about its business [3]. Group 3: Impact on Stock Price - Following a sales guidance reduction on October 23, 2025, Integer's stock price fell by $35.22 per share, a decline of over 32% in one trading day [4].

This press release includes certain statements that are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or Baird Medical's future financial or operating performance. In some cases, you can identify forward-looking statements by terminology such as "may", "could", "should", "expect", "intend", "might", "will", "estimate", "an ...

Group 1: Capital One Financial Corporation - Capital One Financial reported worse-than-expected fourth-quarter adjusted EPS results and announced plans to acquire Brex [1] - Shares of Capital One Financial dipped 7.6% to close at $217.30 [4] Group 2: Medtronic plc - Bernstein analyst Lee Hambright maintained an Outperform rating for Medtronic and raised the price target from $111 to $112 [2] - Barclays analyst Matt Miksic also maintained an Overweight rating and increased the price target from $111 to $116 [2] - Medtronic shares fell 0.5% to settle at $100.88 during the session [4] Group 3: Transocean Ltd. - Transocean is scheduled to report earnings for the fourth quarter and issue a fleet status report on February 19 [3] - Jim Lebenthal named Transocean as his final trade [2] - Transocean shares gained 2.8% to close at $4.83 [4] Group 4: Caterpillar Inc. - Stephen Weiss picked Caterpillar as his final trade [3] - Wells Fargo analyst Jerry Revich maintained an Overweight rating for Caterpillar and raised the price target from $675 to $702 [3] - Caterpillar shares fell 3.4% to close at $626.62 during the session [4]

Core Insights - SciSparc Ltd. has acquired an IP portfolio from Xylo Technologies, including the MUSE™ system, targeting the global multi-billion dollar GERD device market [1][4] - The MUSE™ system is designed for transoral fundoplication, a minimally invasive procedure for treating gastroesophageal reflux disease (GERD) [2] - SciSparc plans to commercialize these technologies immediately and aims for rapid market penetration and revenue generation [2] Market Opportunity - The global GERD device market was valued at approximately $2.5 billion in 2024 and is projected to reach $3.03 billion by 2030, with a CAGR of 3.24% from 2025 to 2030 [5] - SciSparc intends to replicate Xylo's successful commercialization model from Greater China in high-growth regions like North America, Europe, and Latin America [3] Acquisition Details - SciSparc acquired the complete portfolio of patents and related intellectual property rights associated with the MUSE™ system, issuing shares that represent 19.99% of its outstanding share capital to Xylo [4]

Core Viewpoint - A class action lawsuit has been filed against Integer Holdings Corporation and its senior executives for securities fraud following a significant drop in stock price due to alleged violations of federal securities laws [1][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Southern District of New York, titled West Palm Beach Firefighters' Pension Fund v. Integer Holdings Corporation, et al., No. 1:25-cv-10251 [3]. - Investors have until February 9, 2026, to request to lead the case [3]. Group 2: Company Performance and Allegations - Integer designs and manufactures cardiac rhythm management and cardiovascular products, including electrophysiology devices [4]. - The company allegedly overstated demand for its EP devices while public assurances contradicted the actual decline in demand and revenue from these products [5]. - On October 23, 2025, Integer lowered its 2025 sales guidance to between $1.840 billion and $1.854 billion, down from a previous range of $1.850 billion to $1.876 billion, which was below analysts' expectations [6]. - The company projected poor net sales growth of -2% to 2% and organic sales growth of 0% to 4% for 2026, admitting that two of its EP devices had slower than expected adoption [6]. Group 3: Stock Impact - Following the announcement of lowered sales guidance, Integer's stock price dropped by $35.22 per share, a decline of over 32%, from $109.11 per share on October 22, 2025, to $73.89 per share on October 23, 2025 [6].

Treasury Updates - Sharps Technology, Inc. has adopted a digital asset treasury strategy focused on accumulating SOL, the native digital asset of the Solana blockchain, leveraging capital markets raises to power on-chain yield generation with the Solana Ecosystem [6] - The company's validator partners have generated approximately 7% gross annual percentage yield (APY) before fees, outperforming the Solana network average, with nearly all of the company's SOL holdings currently staked [6] - The company maintains sufficient operating capital and has no corporate debt, indicating a strong financial position [6] Recent Operational Highlights - The company continues to deliver strong revenue from its SOL holdings due to its integration with institutional-quality staking infrastructure [1] - Partnerships with leading validator platforms, combined with institutional-grade controls and execution discipline, position the company to capitalize on the financial benefits of the Solana network [1] - In January, the company launched a jointly supported institutional-grade Solana validator in partnership with Coinbase, delegating a portion of its SOL treasury holdings [6]

Core Viewpoint - The company has received a medical device registration certificate from the National Medical Products Administration for its reproductive tract pathogen five-item nucleic acid testing kit, which is expected to enhance its product offerings and market competitiveness [1] Group 1: Product Development - The product is designed for in vitro qualitative detection of Neisseria gonorrhoeae (NG), Chlamydia trachomatis (CT), Ureaplasma urealyticum/Ureaplasma parvum (Uu/Up), Mycoplasma hominis (MH), and Mycoplasma genitalium (MG) in male urethral and female cervical samples [1] - The acquisition of the medical device registration certificate enriches the company's product variety, which is crucial for improving its core competitiveness and market expansion capabilities [1] Group 2: Market Impact - The actual sales performance of the product will be influenced by factors such as market promotion effectiveness and changes in the market environment, indicating a degree of uncertainty [1]

Core Insights - Beta Bionics experienced a significant decline in stock price following the release of preliminary fourth-quarter 2025 performance metrics that did not meet market expectations [1] - The company reported lower-than-expected new patient starts for its iLet automated insulin delivery system, raising concerns among investors about short-term adoption trends and revenue growth [1] - On January 9, 2026, Beta Bionics' stock fell approximately $11.85, or 37.04%, closing at $20.14 [1]

We recently compiled a list of the 12 Cheap Small-Cap Stocks to Invest In Before the Next Breakout.  STAAR Surgical Company tops our list for being one of the best small-cap stocks on our list. TheFly reported on January 16 that Morgan Stanley resumed coverage of STAA with an Underweight rating and a $13 price target following the termination of its merger agreement with Alcon (ALC). The firm described STAAR’s EVO ICL technology as “impressive” but noted it remains a niche product with a limited addressab ...